Point-of-Care Testing (POCT): Regulatory Requirements, CLIA Waivers, and Market Trends

Comprehensive guide to point-of-care testing regulation — CLIA waiver requirements, FDA review pathways for POCT devices, EU IVDR classification, quality management, and the rapidly growing near-patient testing market.

What Is Point-of-Care Testing?

Point-of-care testing (POCT) refers to medical diagnostic testing performed at or near the site of patient care — anywhere outside a traditional centralized laboratory. The defining characteristic is immediacy: the test is performed and the result is available in the same clinical encounter, enabling real-time decision-making without the delays inherent in sending specimens to a reference laboratory.

POCT goes by several names depending on the context: near-patient testing, bedside testing, rapid diagnostics, decentralized testing, and ancillary testing. Regardless of the label, the core concept is the same — bringing the analytical process to the patient rather than transporting the patient's specimen to the process.

Where POCT Happens

Point-of-care testing occurs across a remarkably broad range of settings:

Hospital bedside and emergency departments — Blood gas analysis, cardiac troponin, glucose monitoring, coagulation testing, and rapid infectious disease panels performed by nurses, respiratory therapists, or emergency physicians.
Physician office laboratories (POLs) — Strep tests, urinalysis, pregnancy tests, HbA1c, lipid panels, and basic metabolic panels performed by medical assistants or nursing staff.
Pharmacies and retail clinics — Rapid strep, flu, COVID-19, blood glucose, cholesterol, and HbA1c testing performed by pharmacists or pharmacy technicians.
Urgent care and ambulatory surgery centers — Rapid diagnostics for triage, pre-operative screening, and acute care decision-making.
Long-term care and skilled nursing facilities — Glucose monitoring, INR testing, urinalysis, and influenza/COVID testing.
Field and disaster settings — Military field hospitals, emergency response sites, mobile health units, and resource-limited settings.
Home — Over-the-counter pregnancy tests, blood glucose meters, COVID-19 antigen tests, INR monitors, and continuous glucose monitors used by patients themselves.

POCT vs Central Laboratory Testing

Aspect	Point-of-Care Testing	Central Laboratory Testing
Turnaround time	Minutes (typically 2–30 min)	Hours (often 1–4 hours, sometimes longer)
Operator	Nurses, physicians, medical assistants, pharmacists, patients	Licensed medical technologists/laboratory scientists
Sample volume	Very small (capillary blood, saliva, nasal swab)	Standard venipuncture or larger specimen volumes
Test menu	Limited per device; focused on specific analytes	Comprehensive; hundreds of analytes on automated platforms
Analytical performance	Generally acceptable but may have wider imprecision	Gold standard analytical accuracy and precision
Cost per test	Higher reagent cost per test; lower infrastructure cost	Lower reagent cost per test; higher infrastructure cost
Regulatory complexity	CLIA-waived or moderate complexity; specific usability requirements	High complexity; full laboratory accreditation
Connectivity	Increasingly connected but historically standalone	Fully integrated with LIS/EHR
Quality oversight	POCT coordinator, limited QC frequency	Full laboratory quality program with extensive QC

Advantages and Limitations

Advantages:

Dramatically reduced turnaround time enables faster clinical decisions
Reduced pre-analytical errors (no transport, reduced specimen degradation)
Smaller sample volumes — critical for neonates and patients with difficult venous access
Improved patient satisfaction and clinic throughput
Enables testing in settings where central laboratory access is unavailable
Supports telehealth and decentralized care models

Limitations:

Higher per-test reagent costs compared to high-volume automated platforms
Narrower analytical performance (wider CV, potential for interference)
Operator variability — non-laboratory-trained users may introduce errors
Quality management challenges — devices distributed across many locations
Connectivity and data management complexity
Regulatory burden of CLIA waiver studies for manufacturers
Risk of inappropriate clinical reliance on less precise results

The POCT Market Landscape

Market Size and Growth

The global POCT market was valued at approximately $45–50 billion in 2024 and is projected to reach $75–90 billion by 2030, growing at a compound annual growth rate (CAGR) of 8–10%. The COVID-19 pandemic was a transformative event for the POCT industry, accelerating adoption by years and permanently expanding the range of settings where near-patient testing is considered routine.

Before COVID-19, the POCT market was growing at roughly 6–7% annually. The pandemic surge — driven by the massive global demand for rapid antigen and molecular tests — pushed growth rates above 20% in 2020 and 2021. While the acute pandemic-driven revenue spike has normalized, the lasting impact is structural: healthcare systems, consumers, and regulators have all become more comfortable with decentralized testing, and the infrastructure (both technical and regulatory) built during the pandemic continues to support growth.

Key Market Segments

Segment	Market Share	Key Growth Drivers
Glucose monitoring	~30%	Diabetes prevalence, CGM adoption, value-based care
Cardiac markers	~10%	High-sensitivity troponin POCT, chest pain pathways, ED throughput
Infectious disease	~20%	COVID legacy, multiplex respiratory panels, STI testing, antimicrobial stewardship
Coagulation (INR)	~8%	Anticoagulation self-management, warfarin monitoring
Blood gas/electrolytes	~10%	Critical care demand, OR and ED use
HbA1c	~5%	Diabetes management, same-visit treatment adjustment
Urinalysis	~5%	UTI diagnosis, pregnancy screening, drug testing
Pregnancy/fertility	~4%	Consumer demand, OTC access, fertility tracking technology
Drug of abuse	~3%	Workplace testing, pain management, addiction treatment
Other (lipids, CRP, D-dimer, etc.)	~5%	Expanding test menus, multiplexing

Major Manufacturers

The POCT market is served by a mix of large diversified diagnostics companies and focused POCT specialists:

Abbott — i-STAT (blood gas, electrolytes, cardiac), BinaxNOW (infectious disease), FreeStyle (glucose/CGM)
Roche Diagnostics — cobas Liat (molecular POCT), Accu-Chek (glucose), CoaguChek (INR)
Siemens Healthineers — Xprecia Stride (INR), Epoc (blood gas), RAPIDPoint (blood gas)
Danaher/Beckman/Radiometer — ABL series (blood gas), AQT90 FLEX (immunoassay POCT)
Quidel/QuidelOrtho — Sofia (immunofluorescence rapid testing), Solana (molecular)
Hologic — Panther Fusion (molecular, lab-based but with near-patient models)
Cepheid (Danaher) — GeneXpert (molecular POCT, TB, HIV, flu, COVID, STIs)
Instrumentation Laboratory/Werfen — GEM Premier (blood gas)
Nova Biomedical — StatStrip (glucose), StatSensor (creatinine)
Dexcom — G7, Stelo (continuous glucose monitoring)
Sekisui Diagnostics — OSOM (rapid lateral flow tests)
Chembio Diagnostics — DPP (dual-path platform rapid tests, HIV)
bioMerieux — BioFire FilmArray (molecular syndromic panels)

COVID-19 Impact

The COVID-19 pandemic reshaped the POCT industry in several lasting ways:

Regulatory acceleration — The FDA issued hundreds of Emergency Use Authorizations (EUAs) for POCT devices, including the first OTC molecular test (Lucira) and numerous OTC antigen tests (BinaxNOW, iHealth, InteliSwab, Flowflex). This demonstrated that rapid regulatory pathways could work for POCT without compromising safety.
Consumer familiarity — Hundreds of millions of consumers worldwide used self-tests for the first time. The concept of home-use diagnostics went from niche (pregnancy and glucose) to mainstream.
Manufacturing scale — POCT manufacturers built massive production capacity for lateral flow tests. This capacity is now being redirected toward multiplex respiratory panels, STI tests, and other applications.
Reimbursement expansion — CMS and private payers established new reimbursement mechanisms for POCT, particularly for infectious disease testing in non-traditional settings.
Supply chain lessons — The acute shortages of 2020 (swabs, reagents, test kits) drove investment in domestic manufacturing and supply chain resilience.

Pre-Analytical, Analytical, and Post-Analytical Phases

Understanding the total testing process is essential for managing POCT quality. Like central laboratory testing, POCT follows a three-phase model — but the distribution of errors across these phases differs significantly from the traditional laboratory.

Pre-Analytical Phase

The pre-analytical phase encompasses everything before the sample is analyzed: patient identification, test ordering, specimen collection, specimen handling, and sample loading. In POCT, this phase is especially vulnerable because it is performed by non-laboratory personnel in uncontrolled environments.

Common pre-analytical errors in POCT:

Patient misidentification — Failure to verify patient identity before testing, particularly in busy emergency departments or inpatient settings where multiple patients are being tested simultaneously
Specimen collection errors — Poor lancing technique for capillary blood, using a previously punctured site, milking the puncture site (causing hemolysis and tissue fluid contamination), insufficient blood volume, performing a finger-stick on the same side as a peripheral IV infusing dextrose or other interfering substances
Sample handling errors — Air bubbles in blood gas samples, clotted samples due to improper mixing, delayed analysis after specimen collection (e.g., glucose consumption in whole blood at room temperature), improper storage temperature before testing
Interference sources — Hemolysis from aggressive capillary sampling, hematocrit effects on glucose meters, interference from medications (acetaminophen, vitamin C, maltose in some glucose meters), contamination from alcohol swabs not fully dried before lancing

Key difference from laboratory testing: Research consistently shows that while 60–80% of laboratory errors occur in the pre-analytical and post-analytical phases, POCT errors are more evenly distributed across all three phases, with a notably higher proportion of analytical errors compared to central laboratory testing. This is because POCT devices are operated by less experienced personnel in less controlled environments.

Analytical Phase

The analytical phase covers the actual measurement — from sample application to result generation. In central laboratories, this phase is highly controlled, but POCT analytical errors can be significant.

Common analytical errors in POCT:

Calibration drift — Undetected calibration changes between QC events, particularly in devices with long QC intervals
Reagent and consumable issues — Expired test strips or cartridges, reagents stored outside recommended temperature range, lot-to-lot variability not captured by QC
Operator technique errors — Under-filling or over-filling test strips, incorrect timing of manual steps, improper mixing of reagents
Environmental factors — Temperature and humidity outside operating range, ambient light interference for optical readers, altitude effects on blood gas analyzers
Device malfunction — Sensor degradation, mechanical failures, software errors not caught by built-in diagnostics

Post-Analytical Phase

The post-analytical phase includes result reporting, interpretation, clinical action, and documentation.

Common post-analytical errors in POCT:

Reporting errors — Manual transcription mistakes when entering results into the EHR, failure to report critical values in a timely manner, results not associated with the correct patient
Interpretation errors — Misinterpretation of qualitative test results (faint lines on lateral flow tests), failure to recognize limitations (e.g., treating a negative rapid antigen test as definitive when clinical suspicion is high), applying incorrect reference ranges
Documentation failures — Results not captured in the patient's medical record, missing operator identification, failure to document QC performed before patient testing
Delayed turnaround time — Ironically, one of the main advantages of POCT can be negated by delays in acting on or communicating results

Error Prevention Strategies

Effective POCT error prevention requires a multi-layered approach:

Standardized workflows — Written SOPs for every step from patient identification through result reporting, available at every POCT site
Connectivity and middleware — Electronic capture of results eliminates transcription errors, operator lockout prevents unauthorized testing, QC lockout prevents patient testing when QC is overdue
Competency-based training — Initial training with observed performance, periodic competency reassessment (at least annually), remediation for operators who demonstrate technique issues
Designed-out errors — Device manufacturers increasingly design POCT systems to minimize human error through automated sample detection, built-in timers, digital result display (eliminating subjective visual interpretation), and barcode scanning for patient identification
Real-time monitoring — Centralized dashboards that flag QC failures, unusual result patterns, and operator-specific error rates across all POCT sites

FDA Regulatory Framework for POCT

Device Classification

POCT devices are regulated by the FDA as in vitro diagnostic (IVD) devices under 21 CFR Part 809. Like all IVDs, POCT devices are classified into Class I, Class II, or Class III based on risk:

Class I (low risk) — Some simple POCT devices (e.g., certain urine dipsticks, some specimen collection devices). Generally exempt from premarket notification, though still subject to general controls.
Class II (moderate risk) — The majority of POCT devices fall here, including glucose meters, rapid strep tests, INR monitors, blood gas analyzers, HbA1c analyzers, and most rapid antigen tests. Require 510(k) clearance.
Class III (high risk) — Novel POCT devices without a predicate, or devices for high-risk applications (e.g., first-of-kind companion diagnostics at point of care). Require Premarket Approval (PMA) or may use the De Novo pathway to establish a new Class I or II classification.

510(k) Pathway for POCT

Most POCT devices reach the US market through the 510(k) premarket notification pathway. The manufacturer must demonstrate that the new device is substantially equivalent to a legally marketed predicate device. For POCT, the 510(k) submission typically includes:

Analytical performance data (accuracy, precision, linearity, reportable range, interference, specimen type comparison)
Clinical performance data (method comparison with a reference/predicate method)
If seeking CLIA-waived status, a separate CLIA waiver application and study data (discussed in detail below)
Labeling, including instructions for use appropriate to the intended user
Software documentation (if applicable), per FDA guidance on IVD software
Biocompatibility data if the device contacts the patient (e.g., lancets, swab components)

De Novo Pathway

For novel POCT devices that lack a suitable predicate but are low-to-moderate risk, the De Novo classification pathway provides an alternative to the Class III PMA route. The De Novo request asks the FDA to create a new regulatory classification (typically Class I or II) with special controls tailored to the device type.

Several important POCT device types reached the market through De Novo, including:

The first OTC COVID-19 antigen tests
The first OTC molecular infectious disease tests
Certain novel biomarker POCT devices (e.g., first POCT high-sensitivity troponin)
First-of-kind multiplexed POCT panels

Once a De Novo classification is granted, it establishes a new product code and predicate pathway, meaning subsequent similar devices can use the 510(k) route.

OTC vs Prescription POCT

A critical regulatory distinction for POCT is whether the device is intended for professional use, prescription home use, or over-the-counter (OTC) use:

Category	Intended User	Setting	Regulatory Implications
Professional use	Healthcare professionals or trained operators	Hospitals, clinics, POLs	Standard analytical/clinical performance expectations
Prescription home use	Patients, under physician order	Home	Human factors studies with lay users; enhanced labeling; CLIA considerations
OTC (home use)	General public, no physician oversight	Home, retail purchase	Most stringent usability requirements; lay-user labeling per 21 CFR 809.10(b); typically CLIA-waived

21 CFR 809.10(b) — For OTC IVDs, the labeling must be written so that it is understandable to the lay user, including clear step-by-step instructions, interpretive information, limitations, and when to seek medical attention. The FDA evaluates OTC labeling through the lens of the least sophisticated intended user.

Home-Use IVD Requirements

The FDA guidance document "Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices" and the companion guidance "In Vitro Diagnostic Devices — Guidance for Industry and FDA Staff: Over-the-Counter IVDs" describe the expectations for devices intended for home use. Key requirements include:

Human factors/usability engineering — The manufacturer must conduct formative and summative usability studies demonstrating that untrained lay users can successfully perform the test and interpret the result. This includes studies with participants representing the full range of the intended user population (varying age, education, dexterity, vision).
Labeling comprehension — Studies showing that lay users can correctly understand the instructions for use, warnings, limitations, and result interpretation.
Flex studies — Robustness studies demonstrating that the device performs acceptably under the range of conditions a home user might encounter (temperature extremes, humidity, lighting variations, operator technique variations).
Result interpretation — For qualitative tests, clear visual or digital read-out with minimal ambiguity. For quantitative tests, clear numeric display with units and reference ranges.

Post-Market Surveillance for POCT Devices

Once a POCT device is on the US market, the manufacturer is subject to ongoing FDA post-market surveillance requirements. These obligations apply to all marketed medical devices, but POCT devices face unique challenges due to their distributed use in non-laboratory settings.

Medical Device Reporting (MDR) — 21 CFR Part 803:

Manufacturers must report to the FDA any adverse events involving their devices, including malfunctions that could cause or contribute to a death or serious injury. For POCT devices, MDR events may include:

Device malfunctions leading to incorrect results that caused misdiagnosis or inappropriate treatment
Reagent failures or lot-specific quality issues affecting large numbers of testing sites
Software errors affecting result calculation or display
User injuries (e.g., excessive bleeding from lancets, allergic reactions to swab materials)

Corrections and Removals — 21 CFR Part 806:

Manufacturers must report to the FDA any corrections (on-site fixes) or removals (recalls) of their devices. POCT recalls are particularly challenging because devices may be distributed across thousands of sites — physician offices, pharmacies, hospitals — requiring broad notification and action tracking.

Complaint Handling — 21 CFR 820.198 (now ISO 13485 under QMSR):

Manufacturers must maintain a complaint handling system that captures, investigates, and responds to complaints from POCT users. Given the high volume of POCT devices in the field and the diversity of operators, robust complaint trending is essential for detecting systematic quality issues.

Post-Market Surveillance Studies — 21 CFR Part 822:

For certain higher-risk POCT devices, the FDA may require post-market surveillance studies to gather long-term performance data in real-world conditions. This is particularly relevant for novel POCT technologies where pre-market clinical data may be limited.

Risk Management for POCT Devices

POCT manufacturers must implement a comprehensive risk management process throughout the device lifecycle per ISO 14971:2019 (Medical devices — Application of risk management to medical devices). Risk management for POCT devices requires special attention to:

Use-related risks — POCT devices are used by operators with widely varying training levels in uncontrolled environments. The risk analysis must account for foreseeable misuse by non-laboratory-trained operators, including incorrect specimen collection, improper technique, and result misinterpretation.
Environmental risks — Temperature, humidity, altitude, lighting, and vibration conditions at POCT sites may differ dramatically from laboratory conditions. Risk analysis must address device performance under the full range of anticipated environmental conditions.
Connectivity risks — Networked POCT devices introduce risks related to data integrity, cybersecurity, and system interoperability. Loss of connectivity could lead to unreported results or missed critical values.
Maintenance and calibration risks — In distributed POCT networks, devices may not receive maintenance or calibration as frequently as laboratory instruments. Risk controls must account for extended intervals between preventive maintenance events.

The risk management file should be maintained throughout the product lifecycle and updated as post-market data reveal new hazards or changes in the risk profile.

CLIA and CLIA Waiver

What Is CLIA?

The Clinical Laboratory Improvement Amendments of 1988 (CLIA) is a US federal law that regulates all laboratory testing performed on human specimens for the purpose of diagnosis, prevention, or treatment of disease. CLIA is administered jointly by CMS (Centers for Medicare and Medicaid Services), the FDA, and the CDC.

CLIA classifies tests — not laboratories — into three categories of complexity:

Waived tests — Simple tests with an insignificant risk of an erroneous result, or tests cleared by the FDA for home use. Sites performing only waived tests need a Certificate of Waiver and must follow manufacturer instructions.
Moderate complexity tests — Tests requiring some training and quality oversight. Sites must have a CLIA certificate for moderate complexity and comply with personnel, QC, proficiency testing, and other CLIA standards.
High complexity tests — Tests requiring significant training, judgment, and quality oversight (e.g., manual cell differentials, complex molecular assays, flow cytometry). Full CLIA compliance with the most stringent personnel and QC requirements.

CLIA Certificate Types

Certificate Type	Scope	Requirements
Certificate of Waiver (CoW)	Waived tests only	Follow manufacturer's instructions; subject to CMS inspection
Certificate of Provider-Performed Microscopy (PPM)	Waived tests + certain microscopy procedures	Physician or midlevel provider performs the microscopy
Certificate of Registration	Moderate and/or high complexity (temporary, while applying)	Interim certificate pending survey
Certificate of Compliance	Moderate and/or high complexity (post-survey)	Full CLIA compliance demonstrated through CMS survey
Certificate of Accreditation	Moderate and/or high complexity	Accredited by a CMS-approved accreditation organization (CAP, COLA, TJC, etc.)

Why CLIA waiver matters commercially: As of 2025, there are over 300,000 CLIA-certified sites in the United States. Roughly 70% of these sites — over 200,000 — hold only a Certificate of Waiver. This means they can only perform CLIA-waived tests. If your POCT device is not CLIA-waived, it is effectively locked out of the majority of potential US testing sites. For most POCT manufacturers, obtaining CLIA-waived status is not optional — it is a commercial necessity.

CLIA Waiver Categories

A test can achieve CLIA-waived status through three mechanisms:

Waived by statute — Certain tests are waived by the CLIA statute itself, regardless of the specific device. These include: (a) certain microscopy tests when performed by a physician, (b) dipstick or tablet reagent urinalysis (non-automated), and (c) ovulation tests (visual color comparison for luteinizing hormone), and (d) urine pregnancy tests (visual color comparison).
Waived by FDA/CDC determination — Tests that the FDA determines (based on data submitted by the manufacturer) are "simple" and have "an insignificant risk of an erroneous result." This is the most common pathway for POCT manufacturers and requires a CLIA waiver by application study.
Home-use clearance — Any test cleared or approved by the FDA for home use is automatically CLIA-waived when used in a professional setting. This is because if an untrained consumer can perform the test, it is by definition simple enough for waiver.

How to Obtain CLIA-Waived Status

For manufacturers seeking CLIA waiver by application, the process involves:

Obtain 510(k) clearance (or PMA/De Novo) first — The device must be legally marketed before (or concurrent with) the CLIA waiver determination. Many manufacturers submit the 510(k) and CLIA waiver application simultaneously.
Conduct a CLIA waiver study — The FDA guidance document "Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices" (most recently updated) describes the study design in detail.
Submit the CLIA waiver application to the FDA — The application is reviewed by the FDA's Division of Microbiology Devices or the appropriate review division, depending on the analyte.
FDA review and decision — If the data demonstrate that the device is simple and has an insignificant risk of erroneous results when used by the intended CLIA-waived operator, the FDA grants waived status.

Common Reasons for CLIA Waiver Denial

Unacceptable error rates — Too many incorrect results when the test is performed by non-laboratory-trained operators, particularly for results near the medical decision point.
Operator errors — Failure to follow instructions, incorrect specimen handling, misinterpretation of results, and incomplete testing observed during the waiver study.
Complex procedure — The test requires steps that are too difficult for the intended waived operator (multiple timed steps, precise pipetting, complex sample preparation).
Inadequate labeling — Instructions for use that are unclear, ambiguous, or require training beyond what a waived-site operator would receive.
Insufficient study size or design flaws — Too few specimens, inadequate representation of the measuring range, insufficient challenge near medical decision points, or inappropriate reference method.
Device reliability issues — Excessive device failures, lot-to-lot variability, or environmental sensitivity observed during the waiver study.

CLIA Waiver Study Design

The CLIA waiver study is one of the most critical — and most expensive — regulatory activities for a POCT manufacturer. A well-designed waiver study can take 6–12 months and cost $1–5 million depending on the analyte and complexity.

Study Objectives

The waiver study must demonstrate two things:

Simplicity — The test can be performed correctly by the intended waived-site operator (non-laboratory-trained personnel) using only the manufacturer's instructions for use.
Insignificant risk of erroneous result — The test produces accurate results when used by waived-site operators under real-world conditions, with error rates that do not pose a clinically significant risk.

Study Population and Sites

Sites — The study must be conducted at actual CLIA-waived or intended-for-waiver sites (physician offices, pharmacies, clinics) — not laboratories. A minimum of 3 sites is typical; many studies use 5–10 sites.
Operators — The operators must be representative of the intended user — medical assistants, nurses, pharmacy technicians, or other non-laboratory-trained personnel. Each operator should receive no training beyond what is provided in the device's instructions for use and quick reference guide. No bench training, no one-on-one coaching, and no observation-based correction during testing.
Specimens — Fresh patient specimens are strongly preferred. Contrived or spiked specimens may supplement fresh specimens for rare analyte levels, but the study must include a substantial proportion of real clinical specimens.

Study Design Elements

Element	Requirement
Comparison method	FDA-cleared reference method or predicate device operated by trained laboratory personnel
Minimum sample size	Typically 120+ patient specimens for quantitative assays; FDA guidance recommends adequate representation across the measuring range
Medical decision point coverage	Must include sufficient specimens near the clinical cutoff(s) — e.g., for glucose, specimens near 70 mg/dL (hypoglycemia) and 126 mg/dL (diabetes diagnosis)
Qualitative tests	Must include adequate positive and negative specimens; for infectious disease, must include specimens with a range of analyte concentrations, including weak positives near the limit of detection
Operator observation	An observer records operator technique, errors, deviations from instructions, and any difficulties — without intervening or providing guidance
Result recording	Both the waived-site operator result and the reference laboratory result are recorded for each specimen
Environmental conditions	Testing is performed under the conditions typical of the waived site (ambient temperature, lighting, etc.)

Flex Studies

Flex studies (robustness studies) are a critical component of the CLIA waiver package. They evaluate device performance under conditions that deviate from ideal, simulating real-world misuse and environmental variation. Common flex study variables include:

Temperature — Testing at the extremes of the device's operating range (e.g., 15°C and 30°C rather than the typical 20–25°C)
Humidity — High and low humidity conditions
Specimen handling — Delayed testing, specimens stored at improper temperatures, specimens from different collection methods
Operator technique variation — Under-filling or over-filling the sample, incorrect timing, improper mixing
Reagent/kit stress — Testing with reagents near expiration, reagents stored at temperature extremes
Altitude — For devices affected by atmospheric pressure

Scoring Criteria

For quantitative assays, the FDA typically evaluates accuracy using criteria such as:

Percentage of results within a defined accuracy window (e.g., within +/-12% of the reference for glucose > 75 mg/dL, or within +/-12 mg/dL for glucose <= 75 mg/dL)
Regression analysis (slope, intercept, correlation coefficient)
Bland-Altman analysis (bias and limits of agreement)
Clinically significant error rate (percentage of results that would lead to an incorrect clinical decision)

For qualitative assays, the FDA evaluates:

Sensitivity (positive percent agreement with the reference method)
Specificity (negative percent agreement with the reference method)
Invalid rate (percentage of tests that produce no result)
User error rate (percentage of tests performed incorrectly by the operator)

Critical threshold: The FDA does not publish a single pass/fail number for waiver studies, but the general expectation is that performance in the hands of waived-site operators should be comparable to performance in the hands of trained laboratory personnel. A significant degradation in performance when moving from the laboratory to the waived site is a red flag. For qualitative tests, the FDA generally expects sensitivity and specificity above 95% for waived-site operators, with closer scrutiny for tests where false negatives have serious clinical consequences (e.g., HIV, high-sensitivity troponin).

Labeling for Waived Tests

If CLIA waiver is granted, the device labeling must include:

A statement that the test is CLIA-waived
The CLIA complexity categorization
Instructions for use written for the non-laboratory-trained intended operator
A quick reference guide or quick start card
Clear specimen collection instructions
Unambiguous result interpretation guidance
Limitations of the test, including when confirmatory testing is recommended

2025 CLIA Regulatory Updates for POCT

In January 2025, significant CLIA regulatory updates went into full effect, representing the first major overhaul of CLIA requirements in decades. These changes have direct implications for POCT programs nationwide.

Proficiency Testing Changes

The most impactful change for POCT involves updated proficiency testing (PT) requirements, particularly for hemoglobin A1c — one of the most widely performed point-of-care tests:

HbA1c is now a regulated analyte under CLIA PT — Laboratories performing non-waived HbA1c testing must now participate in proficiency testing and meet defined performance criteria.
CMS performance standard: +/- 8% performance range for HbA1c PT
CAP performance standard: +/- 6% accuracy threshold for evaluating HbA1c PT results
Corrective action required: Labs with PT results falling outside these limits must implement corrective actions and document the resolution

Personnel Qualification Updates

The 2024 CLIA Final Rule (effective January 2025) revised qualification standards for testing personnel:

Nursing degrees: Nursing credentials no longer automatically satisfy requirements for high-complexity testing personnel. However, new pathways under 42 CFR 493.1489(b)(3)(ii) allow nursing graduates to qualify through specific additional coursework and credit requirements.
Grandfathering provision: Personnel who met qualifications before December 28, 2024, and remain in their roles can continue testing under prior criteria. This protects existing POCT operators but means new hires must meet the updated standards.
Moderate-complexity testing: Requirements remain largely unchanged — a high school diploma with documented training and competency assessments continues to be sufficient.

Technical Consultant Qualification Updates

New Technical Consultant (TC) positions now require enhanced credentials:

A degree in chemical, biological, or clinical laboratory science, or
An associate's degree in medical laboratory technology with a minimum of four years of relevant training and experience

Current TCs may continue under previous qualification standards, but all new TC appointments must satisfy the updated requirements. Technical Consultants are responsible for ensuring proper competency assessments, overseeing test performance, and guiding corrective actions — making their qualifications directly relevant to POCT quality.

CMS Paperless Transition

Effective March 1, 2026, CMS is transitioning to a fully electronic system for all CLIA communications. After this date:

Paper fee coupons and paper CLIA certificates will no longer be available
All notifications, fee coupons, and certificates will be delivered electronically via email
Testing sites must ensure their state agency has a current email address on file

This change affects all CLIA-certified sites, including the hundreds of thousands of POCT sites operating under Certificates of Waiver.

State-Level Regulations for POCT

While CLIA provides the federal regulatory floor for laboratory testing, POCT programs must also navigate a complex patchwork of state-level regulations that can significantly affect operations.

State Variation in POCT Requirements

State regulations for POCT vary widely and can be more restrictive than federal CLIA requirements:

State licensure requirements — Some states (e.g., New York, Washington) operate their own laboratory regulatory programs with standards that exceed CLIA. In these "CLIA-exempt" states, POCT sites must comply with state-specific requirements in addition to or instead of CLIA.
Personnel credential requirements — While CLIA allows a high school diploma for waived testing, some states require higher credentials (e.g., licensed medical professionals) or impose state-specific licensure requirements for persons performing laboratory testing in any setting.
Laboratory director requirements — Most states allow a licensed physician to serve as laboratory director for waived testing. However, requirements for who can serve as lab director for POCT vary — some states allow pharmacists, while others do not.
Scope of practice limitations — State laws governing which professionals can order, perform, and interpret POCT vary significantly. For example, the authority for pharmacists to perform and act on POCT results differs from state to state and may be governed by the pharmacy practice act, the state laboratory licensing statute, or both.

Pharmacy POCT: A Case Study in Regulatory Complexity

Pharmacy-based POCT has grown rapidly since COVID-19, but regulatory barriers remain the primary obstacle to further expansion:

Prescriptive authority — A CLIA waiver allows a pharmacy to perform a POCT, but the test itself may still require an order from a prescriber. Some states grant pharmacists independent authority to order POCT; others require a Collaborative Practice Agreement (CPA) with a physician.
Test-and-treat authority — The ability of pharmacists to not just test but also prescribe treatment based on results (e.g., prescribing an antibiotic after a positive strep test) varies by state and is a rapidly evolving area of practice law.
Result reporting — Many states have specific reporting requirements for certain test results (e.g., reporting positive infectious disease results to the state health department), and pharmacies performing POCT must comply with these reportable disease laws.
Regulatory confusion — Research has documented considerable confusion among state regulatory agencies about what is required for pharmacy-based POCT services. The legal authority for laboratory testing is often spread across multiple state laws — not just the pharmacy practice act — creating uncertainty for pharmacies seeking to offer testing.

Practical implication: Before implementing any POCT program, whether in a pharmacy, physician office, clinic, or other setting, it is essential to consult the applicable state's specific requirements in addition to federal CLIA regulations. State requirements for licensure, personnel, laboratory director qualifications, result reporting, and scope of practice may differ materially from federal standards.

The FDA LDT Rule and Its Impact on the POCT Landscape

The FDA's 2024 final rule on laboratory-developed tests (LDTs) — and its subsequent reversal — is a significant regulatory event that affects the broader IVD and POCT ecosystem.

Background

In May 2024, the FDA issued a final rule amending 21 CFR Part 809 to make explicit that in vitro diagnostic products (IVDs) are devices under the Federal Food, Drug, and Cosmetic Act (FD&C Act), "including when the manufacturer of the IVD is a laboratory." The rule established a phased timeline to end the FDA's long-standing enforcement discretion for LDTs, which would have required laboratories to comply with medical device requirements including registration, device listing, MDR, quality systems, and eventually premarket review (510(k), De Novo, or PMA).

Court Ruling and Rescission

In March 2025, the U.S. District Court for the Eastern District of Texas vacated the FDA's rule, concluding that:

LDTs are professional diagnostic services, not medical devices intended for the marketplace
Congress intended CLIA — not the FD&C Act — to govern laboratory testing
The FDA exceeded its statutory authority in attempting to regulate LDTs as devices

The FDA chose not to appeal, and in September 2025 formally rescinded the rule, restoring the pre-2024 regulatory status quo.

Implications for POCT

While the LDT rule primarily affected laboratory-developed tests (not commercially manufactured POCT devices), its passage and reversal have several implications for the POCT landscape:

Commercially manufactured POCT devices remain under FDA oversight — The LDT rule reversal does not affect commercially manufactured POCT devices, which continue to require 510(k) clearance, De Novo authorization, or PMA.
LDTs at POCT sites — Some hospital POCT programs use laboratory-developed or laboratory-modified tests. The restoration of enforcement discretion means these remain under CLIA oversight rather than FDA device regulations.
Innovation signal — The reversal is viewed as a net positive for diagnostic innovation, particularly for laboratories developing novel tests. This may increase competition for commercially manufactured POCT devices from laboratory-developed alternatives.
Future legislation possible — While the rule has been rescinded, Congress may revisit LDT oversight through new legislation. POCT manufacturers and laboratory directors should monitor developments in this area.

EU IVDR Classification for POCT

Under the EU In Vitro Diagnostic Regulation (IVDR, 2017/746), POCT devices are classified based on their intended purpose and risk, with specific provisions for devices intended for self-testing (used by lay persons) and near-patient testing (used by healthcare professionals outside a laboratory environment).

IVDR Classification Rules for POCT

IVDR Class	Risk Level	Examples in POCT	Conformity Assessment
Class A	Lowest risk	General laboratory instruments, specimen containers	Self-certification (no Notified Body required, unless for sterile devices)
Class B	Low-moderate risk	Self-testing devices for non-critical analytes (pregnancy tests, urinalysis)	Notified Body involved for type examination
Class C	Moderate-high risk	Self-testing glucose meters, HbA1c POCT, coagulation POCT, professional-use infectious disease POCT	Notified Body required; technical documentation assessment
Class D	Highest risk	Blood typing/grouping for transfusion, HIV/HBV/HCV screening for blood supply	Notified Body + EU reference laboratory

Self-Testing Devices

Under IVDR, any device intended for use by a lay person (self-testing) is automatically classified one class higher than it would be for professional use, up to a maximum of Class C. This means:

A device that would be Class A for professional use becomes Class B for self-testing
A device that would be Class B for professional use becomes Class C for self-testing
A device that would be Class C for professional use remains Class C for self-testing (does not jump to Class D)

This up-classification reflects the additional risk associated with use by untrained individuals and imposes additional requirements including usability studies, lay-user labeling, and Notified Body oversight.

Near-Patient Testing

The IVDR defines near-patient testing as testing performed outside a laboratory by a healthcare professional in the vicinity of, or at the side of, the patient. Unlike self-testing, near-patient testing performed by a healthcare professional does not trigger automatic up-classification. However, the manufacturer must validate the device for the intended use environment and operator, and the labeling must be appropriate for the near-patient setting.

Notified Body Requirements

For Class B, C, and D POCT devices under IVDR, a Notified Body must be involved in the conformity assessment. This includes review of:

Technical documentation (analytical and clinical performance)
Quality management system (ISO 13485)
Post-market surveillance plan
For self-testing devices: usability/human factors data demonstrating safe use by lay persons
For Class D devices: EU reference laboratory opinion

IVDR transition reality: The IVDR transition has been challenging for the POCT industry. The limited number of designated Notified Bodies for IVDs under IVDR (far fewer than under the old IVDD) has created significant capacity constraints. Many POCT manufacturers, particularly smaller companies, have faced delays in obtaining IVDR certification. The staggered transition timelines (extended through 2027–2029 depending on device class) have provided some relief, but the bottleneck remains a critical industry concern.

Quality Management for POCT

ISO 22870: POCT Quality and Competence

ISO 22870:2016 (Point-of-care testing — Requirements for quality and competence) is the primary international standard specifically addressing quality management for POCT. It is designed to be used in conjunction with ISO 15189 (Medical laboratories — Requirements for quality and competence) and provides additional requirements specific to the decentralized nature of POCT.

ISO 15189:2022 update: The 2022 revision of ISO 15189 now incorporates POCT requirements directly through Annex A, which specifies additional requirements for POCT when carried out in hospitals, clinics, and healthcare organizations offering ambulatory care. This effectively integrates ISO 22870 requirements into the main laboratory accreditation standard, making POCT quality management a mandatory component of ISO 15189 accreditation. Organizations pursuing accreditation should ensure their POCT programs comply with both the main body of ISO 15189:2022 and the specific POCT provisions in Annex A.

Key requirements of ISO 22870 include:

Multidisciplinary POCT committee — The healthcare organization must establish a committee (or equivalent governance structure) responsible for oversight of all POCT activities, including device selection, implementation, quality monitoring, and training. This committee typically includes representatives from laboratory medicine, nursing, pharmacy, IT, infection control, and clinical departments.
POCT coordinator — A designated individual (typically a medical technologist or laboratory manager) responsible for the day-to-day management of the POCT program, including training, competency assessment, quality control, troubleshooting, and communication with the POCT committee.
Operator training and competency — All POCT operators must be trained on each device they use, with documented initial training and periodic competency assessments. Training must cover specimen collection, test performance, result interpretation, quality control, troubleshooting, and safety.
Quality control — Regular internal QC testing per manufacturer requirements, with documented QC results and corrective actions for out-of-range QC.
External quality assessment (EQA) — Participation in proficiency testing programs for each POCT analyte, if available.
Documentation — SOPs for each POCT test, training records, QC records, EQA results, incident reports, and equipment maintenance logs.

POCT Coordinator Role

The POCT coordinator is one of the most important roles in any hospital or health system's POCT program. This individual is the bridge between the clinical laboratory (which typically has ultimate responsibility for POCT quality) and the clinical departments where POCT is performed.

Key responsibilities:

Device evaluation, selection, and validation
Developing and maintaining SOPs for each POCT test
Training and competency assessment for all POCT operators
Quality control management and review
Troubleshooting and corrective actions
Managing POCT device connectivity and data management
Coordinating with vendors for reagent supply, maintenance, and instrument service
Reporting to the POCT committee and laboratory director
Regulatory compliance (CLIA, state regulations, accreditation standards)

Connectivity and Data Management

Modern POCT programs require robust connectivity solutions to ensure that test results are captured in the patient's medical record, operator competency is tracked, and quality control data is centrally monitored. Key standards and systems include:

POCT1-A/POCT1-A2 — The CLSI (Clinical and Laboratory Standards Institute) standard for POCT device connectivity. It defines the communication protocol between POCT devices, device data managers, and laboratory/hospital information systems.
Device data managers (middleware) — Software platforms (e.g., Roche cobas IT 1000, Abbott AlinIQ, Siemens POCcelerator, Telcor QML) that aggregate data from multiple POCT devices, manage operator lockout, enforce QC compliance, and transmit results to the LIS/EHR.
Operator lockout — A feature of device data managers that prevents untrained or non-competent operators from performing POCT. If an operator's training or competency assessment has expired, the middleware locks them out of the device until retraining is completed.
QC lockout — Prevents patient testing if the required QC has not been performed or if QC results are out of range.

EQA and Proficiency Testing

Proficiency testing (PT) for POCT is required by CLIA for non-waived tests and is strongly recommended (and often required by accreditation organizations) even for waived tests. Organizations such as CAP (College of American Pathologists), AAFP (American Academy of Family Physicians), and API (Analytical Proficiency Inc.) offer PT programs specifically designed for POCT.

Reagent and Supply Management

Managing reagent and supply logistics for a distributed POCT program is a significant operational challenge. Key considerations:

Cold chain management — Some POCT reagents require refrigeration; tracking storage conditions across dozens or hundreds of POCT sites is complex.
Lot management — When reagent lots change, the device may require new calibration or QC verification. Coordinating lot changes across a large POCT program requires planning.
Expiration tracking — Ensuring that expired reagents are removed from service at distributed sites.
Par levels and ordering — Maintaining adequate stock at each POCT site without overstocking (which leads to expiration waste).

Key POCT Technologies

Lateral Flow Immunoassay (LFIA)

Lateral flow is the technology behind the most widely used POCT devices in the world — from pregnancy tests to COVID-19 antigen tests. A sample is applied to a pad, migrates along a membrane strip, and interacts with labeled antibodies and capture zones to produce a visible line or signal.

Advantages: Inexpensive, no instrumentation required, room-temperature storage, fast (5–15 minutes), intuitive visual readout
Limitations: Qualitative or semi-quantitative, limited sensitivity compared to laboratory immunoassays, subjective visual interpretation (mitigated by digital readers)
Examples: Abbott BinaxNOW COVID-19 Ag, QuidelOrtho QuickVue, Sekisui OSOM Strep A, BD Veritor

Electrochemical Biosensors

The technology behind glucose meters and many other quantitative POCT devices. An enzyme-coated electrode reacts with the target analyte, generating an electrical signal proportional to the analyte concentration.

Advantages: Quantitative, small sample volume, fast, well-established technology, excellent for blood glucose
Limitations: Susceptible to interferences (hematocrit, maltose, acetaminophen, vitamin C), requires calibration
Examples: Abbott FreeStyle, Roche Accu-Chek, Nova StatStrip, i-STAT (electrochemical and potentiometric sensors)

Microfluidics

Lab-on-a-chip and microfluidic cartridge systems integrate multiple analytical steps (sample preparation, reagent mixing, amplification, detection) into a small disposable cartridge.

Advantages: Minimal sample preparation, automated multi-step protocols, multiplexing capability, reduced reagent consumption
Limitations: Higher per-test cost, cartridge complexity, instrument required
Examples: Abbott i-STAT (cartridge-based blood gas/chemistry), bioMerieux BioFire FilmArray, Cepheid GeneXpert, Radiometer ABL90 FLEX

Optical and Photometric Detection

Many POCT devices use optical detection methods — reflectance photometry, fluorescence, chemiluminescence, or turbidimetry — to measure analyte concentrations.

Advantages: Versatile, can achieve high sensitivity (especially fluorescence), well-suited for immunoassay-based POCT
Limitations: Requires instrumentation, ambient light interference, instrument calibration
Examples: QuidelOrtho Sofia (immunofluorescence), Siemens DCA Vantage (HbA1c, albumin/creatinine), Roche cobas h 232 (cardiac markers)

Molecular POCT

Molecular POCT devices bring nucleic acid amplification testing (NAAT) to the point of care, dramatically reducing turnaround time for molecular diagnostics from hours to minutes.

Isothermal amplification:

LAMP (loop-mediated isothermal amplification), RPA (recombinase polymerase amplification), NEAR (nicking enzyme amplification reaction)
Does not require thermal cycling — simpler instrumentation
Examples: Abbott ID NOW (NEAR-based; COVID-19, influenza, strep, RSV)

Rapid PCR:

Miniaturized real-time PCR systems
Examples: Cepheid GeneXpert (TB, HIV, COVID, STIs, flu — ~30–60 min), Roche cobas Liat (~20 min PCR for flu, COVID, strep)

Sample-to-answer systems:

Fully automated cartridge-based systems requiring no specimen preparation by the operator
Examples: bioMerieux BioFire FilmArray (syndromic panels for respiratory, GI, blood culture, meningitis), Cepheid GeneXpert, Mesa Biotech Accula (now Thermo Fisher)

Smartphone-Connected Devices

An emerging category of POCT devices leverages the smartphone as the reader/analyzer, using the phone's camera, processing power, and connectivity.

Advantages: Low instrument cost (leverages ubiquitous smartphones), built-in connectivity, app-based user interface, remote monitoring capability
Limitations: Variability across phone models, ambient light effects on camera-based reading, regulatory challenges (software as a medical device)
Examples: Ellume COVID-19 Home Test (Bluetooth-connected analyzer), Scanwell Health (urinalysis via smartphone), Healthy.io (urinalysis, wound measurement)

Wearable Continuous Monitoring

Continuous monitoring devices represent the frontier of POCT, providing real-time, continuous analyte measurement without discrete testing events.

Glucose CGM: Dexcom G7, Abbott FreeStyle Libre 3, Medtronic Guardian 4 — subcutaneous sensors measuring interstitial glucose continuously for 10–15 days
Emerging analytes: Continuous lactate, ketone, and alcohol monitoring in development; continuous hemodynamic monitoring
Advantages: Eliminates finger-stick testing, trend data, alarms for out-of-range values, improved outcomes in diabetes management
Limitations: Sensor cost, accuracy lag vs blood glucose, skin reactions, calibration requirements (decreasing with newer generations)

Specific POCT Applications

Glucose Monitoring

Glucose monitoring is the largest and most mature POCT segment. It encompasses:

Blood glucose meters (BGM) — Finger-stick capillary blood testing; used in hospitals, clinics, and home. The FDA has separate accuracy standards for hospital-use glucose meters (stricter, per FDA 2020 guidance) vs home-use meters (per ISO 15197:2013/2023). Key products: Nova StatStrip (hospital), Roche Accu-Chek Guide (home), Abbott FreeStyle (home).
Continuous glucose monitors (CGM) — Subcutaneous sensors providing real-time glucose readings every 1–5 minutes. Originally Class III PMA devices; now some are Class II (e.g., Dexcom Stelo for OTC non-insulin use). The CGM market is rapidly expanding beyond Type 1 diabetes to Type 2 diabetes, gestational diabetes, and even wellness/metabolic health.

Cardiac Troponin

POCT cardiac troponin testing enables rapid rule-in/rule-out of acute myocardial infarction in the emergency department. High-sensitivity cardiac troponin (hs-cTn) assays have traditionally been laboratory-only, but POCT versions are emerging:

Abbott i-STAT TnI — A widely used POCT troponin, though not high-sensitivity
Quidel Triage Troponin I — Fluorescence immunoassay POCT
Siemens Atellica VTLi — Patient-side immunoassay system
Emerging: True high-sensitivity troponin at the point of care is a major unmet need and an active area of development

Clinical significance: The ability to perform high-sensitivity troponin testing at the point of care would fundamentally change emergency department chest pain pathways, enabling 0/1-hour or 0/2-hour rule-out protocols without waiting for central laboratory results. This is one of the most commercially valuable POCT applications in development.

INR/Coagulation

POCT INR (International Normalized Ratio) testing enables monitoring of patients on warfarin therapy. Patient self-testing with POCT INR devices is well-established and has been shown to improve time in therapeutic range and reduce thromboembolic events.

Roche CoaguChek INRange/XS — The market leader in POCT INR, available for professional and patient self-testing
Siemens Xprecia Stride — Professional and patient self-testing
Abbott i-STAT — ACT, PT/INR in the hospital/critical care setting

Infectious Disease Rapid Tests

This segment experienced explosive growth during COVID-19 and continues to expand:

COVID-19: Abbott BinaxNOW, Quidel QuickVue, iHealth, Flowflex (antigen); Abbott ID NOW, Cepheid GeneXpert (molecular)
Influenza A/B: Quidel Sofia, BD Veritor, Abbott ID NOW, Cepheid Xpert Xpress Flu
RSV: Cepheid Xpert Xpress RSV, Quidel Sofia RSV
Strep A: Quidel QuickVue, Sekisui OSOM, Abbott ID NOW Strep A
HIV: OraQuick In-Home HIV Test (the only FDA-approved OTC HIV test), Chembio SURE CHECK, Alere Determine
Multiplex respiratory panels: bioMerieux BioFire FilmArray Respiratory Panel (RP2.1) — 22 targets in ~45 minutes at near-patient settings

Blood Gas and Electrolytes

Critical care POCT for blood gas analysis (pH, pCO2, pO2), electrolytes (Na, K, Cl, Ca), metabolites (lactate, glucose), and co-oximetry (hemoglobin, carboxyhemoglobin, methemoglobin).

Abbott i-STAT — Handheld, cartridge-based, widely used in EDs, OR, ICUs, transport
Radiometer ABL90 FLEX/ABL800 — Benchtop analyzers for high-volume POCT settings
Siemens RAPIDPoint 500e/Epoc — Epoc is a handheld wireless blood gas analyzer
Werfen GEM Premier 5000 — Benchtop with integrated QC

HbA1c

POCT HbA1c enables same-visit diabetes management decisions — the clinician can adjust therapy based on the HbA1c result during the patient encounter rather than waiting for laboratory results.

Siemens DCA Vantage — The most widely used POCT HbA1c analyzer; NGSP-certified
Abbott Afinion 2 — HbA1c, CRP, ACR, lipid panel
Roche cobas b 101 — HbA1c and lipid panel
Bio-Rad in2it/D-100 — POCT and near-patient HbA1c

Urinalysis

POCT urinalysis ranges from simple dipstick tests to automated urine chemistry analyzers:

Manual dipstick — Siemens Multistix, Roche Combur; visual color comparison, CLIA-waived for manual read
Automated readers — Siemens CLINITEK Status+, Roche cobas u 411; semi-automated strip readers that reduce subjective interpretation
Microscopic urinalysis — Not POCT; requires laboratory setting and trained personnel

Drug of Abuse Testing

POCT drug testing is performed in workplace drug testing programs, emergency departments, pain management clinics, and addiction treatment facilities.

Instant cup tests — Integrated urine collection cup with built-in immunoassay strips (e.g., Alere iCup, Abbott Confirm Biosciences)
Oral fluid tests — Abbott SalivaScreen, OraSure Q.E.D.
Confirmatory testing — POCT drug screens are presumptive; all non-negative results require laboratory confirmation by GC-MS or LC-MS/MS

Pregnancy and Fertility

Pregnancy tests (hCG) — The original consumer POCT product; lateral flow immunoassay; OTC and CLIA-waived
Ovulation prediction (LH) — Clearblue, First Response; OTC lateral flow
Fertility hormones — Emerging POCT/consumer devices for FSH, AMH, progesterone confirmation of ovulation (e.g., Mira, Proov)

Home-Use and OTC POCT

FDA Requirements for Home-Use Devices

The FDA applies heightened scrutiny to devices intended for home use by lay persons. The core regulatory concern is that untrained users, without the supervision of a healthcare professional, must be able to:

Collect the specimen correctly
Perform the test correctly
Interpret the result correctly
Take appropriate action based on the result (or understand when to seek professional help)

Human Factors and Usability Studies

For OTC POCT, the FDA expects a comprehensive usability engineering program per FDA guidance and IEC 62366-1:

Formative studies — Iterative design evaluation with representative lay users, identifying usability issues that could lead to use errors
Summative (validation) study — A final study with a statistically significant sample of representative lay users, demonstrating that users can successfully perform the test and interpret the result. The FDA expects to see data on: correct specimen collection rate, correct test performance rate, correct result interpretation rate, and overall test success rate.
Labeling comprehension study — A separate study demonstrating that lay users understand the instructions for use, warnings, and limitations

Labeling Requirements

Per 21 CFR 809.10(b), OTC IVD labeling must:

Be written at an appropriate reading level (generally 6th–8th grade)
Include clear, step-by-step pictorial instructions
Describe what the test is for, what the results mean, and when to see a doctor
Include limitations and potential sources of error
Provide a customer support contact (phone number, website)
Describe proper specimen collection, handling, and disposal

Direct-to-Consumer Models

The COVID-19 pandemic established the direct-to-consumer POCT model at scale. Key DTC models include:

Retail OTC — Tests purchased at pharmacies, grocery stores, or online (Amazon, manufacturer websites) without a prescription
Subscription models — Recurring delivery of test kits (e.g., glucose test strips, COVID tests)
Telehealth-integrated testing — Patient performs a home POCT, uploads results via smartphone app, and conducts a virtual visit with a clinician based on the results (e.g., home STI testing with telehealth consultation)
Employer/payer-distributed testing — COVID-19 test kits distributed by employers or insurance companies

Reimbursement and the Business Case for POCT

CPT Codes and the QW Modifier

POCT is reimbursed through the same Current Procedural Terminology (CPT) codes used for laboratory testing — there is no separate "POCT" fee schedule. The reimbursement is based on the analyte tested, not the testing methodology or setting. Key details:

QW modifier — When a CLIA-waived test is performed at a waived site, the QW modifier is appended to the CPT code (e.g., 82962-QW for CLIA-waived glucose). This modifier identifies the test as waived for billing purposes.
Common POCT CPT codes — 82962 (glucose), 85018-QW (hemoglobin), 83036-QW (HbA1c), 85610-QW (PT/INR), 87880-QW (Strep A rapid test), 87804-QW (influenza), 87426-QW (COVID-19 antigen), 81003-QW (urinalysis dipstick), 82270-QW (fecal occult blood)
Reimbursement rates — Medicare reimbursement for POCT is determined by the Clinical Laboratory Fee Schedule (CLFS), which typically pays the same or less than centralized laboratory testing for the same analyte. Commercial payer rates vary by contract.

The Financial Challenge

POCT presents a paradox: per-test reagent costs are typically higher than centralized laboratory testing, yet reimbursement rates are the same or lower. This creates a direct-cost financial disadvantage for POCT compared to high-volume automated platforms. The financial case for POCT is therefore rarely based on test-level profitability. Instead, POCT value is driven by:

Reduced length of stay — Faster results in emergency departments and inpatient settings can reduce hospital stays by hours or days, generating substantial savings
Improved clinical workflow — Same-visit testing (e.g., POCT HbA1c enabling immediate therapy adjustment, rapid strep enabling immediate antibiotic prescribing) reduces return visits and improves clinic throughput
Avoided downstream costs — Rapid rule-out of acute MI with POCT troponin reduces unnecessary admissions; rapid infectious disease identification reduces empiric broad-spectrum antibiotic use
Patient satisfaction — Faster results improve the patient experience, which increasingly affects hospital reimbursement through value-based care programs (HCAHPS scores, CMS Star Ratings)

Medicare Enrollment for Non-Traditional POCT Sites

Pharmacies, retail clinics, and other non-traditional POCT sites that wish to bill Medicare for POCT must enroll as independent clinical laboratories:

Obtain a CLIA Certificate of Waiver
Submit a CMS-855B enrollment application to the designated Medicare Administrative Contractor (MAC)
Receive a Medicare supplier number
Bill Medicare using the CLFS with appropriate QW modifiers

For Medicaid, enrollment requirements vary by state. Commercial insurance billing depends on individual payer contracts and credentialing requirements.

Value-Based Care and POCT

As healthcare shifts from fee-for-service to value-based payment models, POCT is increasingly recognized as a tool for improving quality metrics and reducing total cost of care:

Quality measures — POCT HbA1c supports HEDIS diabetes management measures; POCT INR supports anticoagulation quality metrics; rapid infectious disease POCT supports antimicrobial stewardship metrics
Care coordination — POCT results available during the clinical encounter enable same-visit care plans, reducing fragmentation and improving continuity
Population health management — POCT deployed in community settings (pharmacies, mobile health units, community health centers) can extend diagnostic access to underserved populations, supporting population health goals
Risk-based contracting — In capitated or shared-savings models, POCT that reduces ED utilization, hospitalizations, and unnecessary referrals has direct financial value to the risk-bearing entity

POCT and Antimicrobial Stewardship

Point-of-care testing is emerging as a critical tool for antimicrobial stewardship programs — efforts to optimize antibiotic prescribing and reduce the development of antimicrobial resistance (AMR).

CRP Testing at the Point of Care

C-reactive protein (CRP) POCT is one of the most evidence-supported applications of POCT for antimicrobial stewardship, particularly in primary care:

Mechanism — CRP is an acute-phase inflammatory marker. Elevated CRP suggests bacterial infection, while low CRP in the context of respiratory symptoms suggests viral etiology. POCT CRP results (available in 3–5 minutes) can help clinicians distinguish bacterial from viral respiratory infections and make more informed prescribing decisions.
Evidence — Multiple randomized controlled trials have demonstrated that CRP POCT in primary care reduces antibiotic prescribing for respiratory tract infections by 20–40% without adverse patient outcomes. Studies in European primary care settings (where CRP POCT is widely adopted) show sustained reductions in antibiotic prescribing.
Adoption — CRP POCT is widely used in European primary care but has seen slower uptake in the US, where it is less commonly reimbursed for this indication. Growing awareness of AMR is driving increased interest.

Rapid Identification and Susceptibility Testing

Molecular and phenotypic POCT for pathogen identification and antimicrobial resistance detection is a rapidly developing area:

Rapid Strep A POCT — Already widely used; enables targeted antibiotic prescribing for pharyngitis, avoiding unnecessary antibiotics for viral sore throats
Rapid influenza and COVID-19 POCT — Distinguishing viral from bacterial respiratory illness at the point of care reduces empiric antibiotic prescribing
Emerging: Rapid AST at POC — Next-generation POCT devices that can provide antimicrobial susceptibility results in hours (rather than days) would enable targeted therapy from the first dose, dramatically reducing broad-spectrum antibiotic use
Procalcitonin POCT — Procalcitonin (PCT) is a biomarker that helps differentiate bacterial from non-bacterial infections and guide antibiotic de-escalation. POCT procalcitonin is emerging as a tool for antibiotic stewardship in emergency departments and critical care

Impact

The WHO has identified AMR as one of the top ten global public health threats. By enabling more targeted antibiotic prescribing, POCT has the potential to meaningfully reduce unnecessary antibiotic consumption — a key driver of resistance.

Health Equity and Access

POCT's Role in Reducing Healthcare Disparities

Point-of-care testing has the potential to reduce healthcare disparities by bringing diagnostic services to underserved populations who face barriers to accessing traditional laboratory testing:

Geographic access — POCT in pharmacies, community health centers, mobile health units, and rural clinics extends diagnostic reach to populations with limited access to hospitals or reference laboratories. Nearly 90% of the US population lives within 5 miles of a pharmacy, making pharmacy-based POCT a powerful tool for expanding access.
Reduced time burden — POCT eliminates the need for separate laboratory visits, multiple appointments, and delayed results — barriers that disproportionately affect low-income and working populations who cannot easily take time off work.
Same-visit diagnosis and treatment — Test-and-treat models (e.g., rapid strep + antibiotic, rapid HIV + linkage to care) reduce loss to follow-up, which disproportionately affects vulnerable populations.
Language and literacy — Well-designed POCT devices with visual/digital readouts and multilingual instructions can reduce barriers for populations with limited English proficiency or low health literacy.

Challenges

Despite its promise, POCT must be deployed thoughtfully to avoid exacerbating disparities:

Cost barriers — OTC POCT costs may be prohibitive for uninsured and underinsured populations unless subsidized by public health programs or insurance coverage
Digital divide — Smartphone-connected and app-dependent POCT devices may exclude populations with limited technology access
Quality assurance in under-resourced settings — Maintaining POCT quality (operator training, QC, device maintenance) is particularly challenging in settings with limited resources and high staff turnover
Cultural considerations — POCT programs in diverse communities require culturally appropriate communication, informed consent processes, and sensitivity to community concerns about testing and data privacy

Site-Level Verification and Validation for POCT

Manufacturer Validation vs. Site Verification

A critical distinction exists between the manufacturer's validation of a POCT device (performed during development and regulatory clearance) and the site-level verification that must occur before the device is used for patient testing at a specific location.

Manufacturer validation — Comprehensive studies establishing the device's analytical and clinical performance under controlled conditions, submitted to the FDA as part of the premarket review. This is the manufacturer's responsibility.
Site-level verification — Studies performed by the healthcare organization implementing the POCT device to confirm that it performs as expected in their specific environment, with their operators, and with their patient population. This is the implementing site's responsibility.

Verification Requirements

For CLIA-waived tests, the regulatory requirement is minimal: the site must follow the manufacturer's instructions for use. No independent verification is required by CLIA for waived tests.

For moderate and high complexity POCT, the implementing site must verify the manufacturer's performance claims, including:

Accuracy — Method comparison with a reference method or the central laboratory analyzer for at least 20–40 patient specimens across the reportable range
Precision — Repeatability (within-run) and within-laboratory (day-to-day) precision using control materials at clinically relevant concentrations
Reportable range — Verification that the device's reportable range is adequate for the patient population
Reference range — Verification or establishment of reference ranges appropriate to the patient population being tested

Even for waived tests, accreditation organizations (CAP, Joint Commission, COLA) may require additional verification activities beyond CLIA's minimal requirements.

ISO 22870 and ISO 15189:2022 Verification Requirements

ISO 22870, used in conjunction with ISO 15189 (and now incorporated into ISO 15189:2022 Annex A), requires that before any POCT device is placed into clinical service, the healthcare organization must:

Evaluate and approve the device through the multidisciplinary POCT committee
Perform method performance verification appropriate to the device and its intended use
Establish that results from the POCT device are comparable to results from the central laboratory for the same analyte (where applicable)
Document the verification results and committee approval
Develop SOPs specific to the device and site
Train all operators and document initial competency

This structured approach ensures that POCT quality is maintained across the distributed testing network and that results from different devices and sites are clinically interchangeable.

Digital Health Integration

Connectivity Standards

POCT1-A/POCT1-A2 — Published by CLSI (Clinical and Laboratory Standards Institute), this standard defines the communication interface between POCT devices and information systems. POCT1-A2 (the current version) specifies a bidirectional protocol that supports:

Patient identification and order download to the POCT device
Result upload from the device to the data manager/LIS
Operator identification and competency verification
QC data management
Device status and error reporting

EHR Integration

Ensuring that POCT results are captured in the patient's electronic health record is critical for clinical decision-making, continuity of care, billing, and regulatory compliance. Integration models include:

Device data manager to LIS/EHR — The most common model; the device data manager (middleware) aggregates results from multiple POCT devices and transmits them to the LIS or directly to the EHR via HL7/FHIR interfaces.
Direct device-to-EHR — Some newer POCT devices can connect directly to the EHR via Wi-Fi or cellular, bypassing the middleware layer. This simplifies architecture but may sacrifice some quality management features.
Manual entry — Still common in smaller settings; the operator manually enters the POCT result into the EHR. This is error-prone and is being phased out in favor of electronic connectivity.

Cloud-Based POCT Data Management

Cloud platforms for POCT management are growing rapidly, offering:

Centralized dashboard for multi-site POCT programs
Remote monitoring of device status, QC compliance, and operator competency
Automated alerts for QC failures, expired reagents, and operator lockout events
Analytics and reporting for utilization, turnaround time, and cost management
Firmware and software updates deployed remotely

Cybersecurity Considerations

As POCT devices become increasingly connected, cybersecurity becomes a regulatory and operational concern. The FDA's premarket cybersecurity guidance applies to networked POCT devices, requiring:

Threat modeling for the device and its communication interfaces
Authentication and access controls
Data encryption in transit and at rest
Software bill of materials (SBOM)
Patch management and update capability
Vulnerability disclosure and incident response

AI/ML in POCT

Artificial intelligence and machine learning are being integrated into POCT in several ways:

Image analysis — AI-powered readers for lateral flow tests, reducing subjective interpretation variability (e.g., Ellume's AI-powered COVID test reader)
Result interpretation — Machine learning algorithms that combine POCT results with patient data to improve diagnostic accuracy (e.g., multi-analyte algorithms for sepsis prediction)
Quality management — AI-driven anomaly detection for QC data, predicting device failures before they occur
Clinical decision support — AI systems that recommend next steps based on POCT results (e.g., antimicrobial stewardship recommendations based on rapid ID/AST results)

Global POCT Regulatory Landscape

WHO Prequalification

The WHO Prequalification of In Vitro Diagnostics Programme evaluates IVDs for use in resource-limited settings, focusing on priority diseases including HIV, malaria, tuberculosis, hepatitis B/C, HPV, and syphilis. POCT devices are a major focus of WHO prequalification because they enable diagnostic testing in settings without laboratory infrastructure.

WHO prequalification involves:

Dossier review (analytical and clinical performance data)
Manufacturing site inspection
Product testing at WHO collaborating laboratories
Post-market surveillance

Prequalification is not a regulatory approval — it is a recommendation to UN procurement agencies (UNICEF, UNDP, Global Fund) and national programs that the product meets WHO quality standards.

ASSURED Criteria

The WHO developed the ASSURED criteria as a framework for evaluating POCT suitability for resource-limited settings:

Letter	Criterion	Description
A	Affordable	Low cost per test, affordable for the target setting
S	Sensitive	Adequate clinical sensitivity to detect true positives
S	Specific	Adequate clinical specificity to minimize false positives
U	User-friendly	Simple to perform, minimal training, few steps
R	Rapid and robust	Fast results, stable at ambient temperature, durable
E	Equipment-free	No or minimal instrumentation required
D	Deliverable	Can be transported and stored in the intended setting

The ASSURED criteria have been updated by some authors to "REASSURED" to add:

R — Real-time connectivity (results transmitted to surveillance systems)
E — Ease of specimen collection (non-invasive specimen types preferred)

Regulatory Frameworks in Developing Countries

Many low- and middle-income countries (LMICs) are developing or strengthening their regulatory frameworks for IVDs, including POCT:

African Medicines Regulatory Harmonization (AMRH) — An AU/NEPAD initiative to harmonize medical product regulation across Africa, including IVDs
ASEAN Medical Device Directive — Harmonized framework for medical device regulation across Southeast Asian nations
India CDSCO — India's Central Drugs Standard Control Organisation regulates IVDs, with increasing attention to POCT for its massive public health programs
Brazil ANVISA — Has established specific requirements for rapid tests and POCT

Access Challenges

Despite the promise of POCT for global health, significant barriers remain:

Regulatory harmonization — Fragmented regulatory requirements across countries increase costs and delay access
Quality assurance — Maintaining POCT quality in resource-limited settings (temperature control, operator training, QC, EQA) is challenging
Procurement and supply chain — Ensuring a consistent supply of reagents and consumables in remote settings
Surveillance integration — Connecting POCT results to national disease surveillance systems
Sustainability — Ensuring long-term funding for POCT programs beyond initial donor support

Emerging Trends in POCT

Lab-on-a-Chip

Microfluidic lab-on-a-chip platforms are advancing toward fully integrated, sample-to-answer systems that can perform complex multi-step assays (sample preparation, amplification, detection) on a single disposable chip. Companies like Fluidigm, Standard BioTools, Agilent, and numerous startups are developing platforms that could bring laboratory-grade testing to the point of care.

CRISPR-Based Diagnostics

CRISPR-based diagnostic platforms (e.g., Sherlock Biosciences, Mammoth Biosciences) leverage the specificity of CRISPR-Cas enzymes for nucleic acid detection. These systems can be combined with lateral flow readout for instrument-free molecular detection, potentially enabling molecular-grade sensitivity in a lateral-flow-test format.

Sherlock Biosciences — SHERLOCK (Cas13-based) and INSPECTR (cell-free synthetic biology) platforms
Mammoth Biosciences — DETECTR (Cas12/Cas14-based) platform
Potential: Room-temperature, instrument-free molecular testing with lateral flow readout — a potential game-changer for infectious disease POCT in resource-limited settings

Multiplexed Panels

The trend toward multiplexed POCT panels — testing for multiple analytes simultaneously from a single specimen — is accelerating:

Respiratory panels: COVID-19 + Flu A/B + RSV in a single POCT test (e.g., Abbott ID NOW respiratory panel development, Cepheid Xpert Xpress CoV-2/Flu/RSV plus)
STI panels: Multiplex POCT for chlamydia, gonorrhea, and trichomonas
Sepsis panels: Multiplex biomarker panels (procalcitonin, CRP, lactate, IL-6) for sepsis triage at the point of care
Antimicrobial resistance: Phenotypic and genotypic resistance detection at the point of care to guide empiric therapy

Decentralized Clinical Trials

POCT is enabling decentralized and hybrid clinical trial designs, where participants perform study-related testing at home or local sites rather than traveling to clinical trial centers. This improves trial access, diversity, and retention while reducing costs.

Wearable Diagnostics

Beyond glucose CGM, wearable diagnostic platforms are in development for:

Continuous lactate monitoring — For athletic performance and critical care
Continuous ketone monitoring — For diabetes management and ketogenic therapy monitoring
Sweat-based analyte monitoring — Non-invasive monitoring of electrolytes, cortisol, glucose, and drugs via sweat sensors
Interstitial fluid monitoring — Microneedle-based patches for continuous monitoring of multiple analytes

AI-Powered POCT

The convergence of AI/ML with POCT is creating new capabilities:

Predictive diagnostics — AI models that combine POCT results with patient history, vital signs, and imaging to improve diagnostic accuracy beyond what any single test can achieve
Autonomous quality management — AI systems that continuously monitor POCT device performance, detect drift, and trigger preventive maintenance before quality degrades
Natural language processing — Voice-guided POCT workflows for hands-free operation in surgical and emergency settings
Federated learning — Distributed AI training across POCT networks that improves algorithms without centralizing sensitive patient data

Frequently Asked Questions

What does CLIA-waived mean?

CLIA-waived means a test has been determined by the FDA to be simple enough to have "an insignificant risk of an erroneous result" when performed by non-laboratory-trained personnel. Sites performing only CLIA-waived tests need a Certificate of Waiver from CMS and must follow the manufacturer's instructions for use. They are subject to less rigorous regulatory oversight than sites performing moderate or high complexity tests. Importantly, CLIA-waived status is specific to the device and test system — the same analyte may be waived on one device and moderate complexity on another.

How long does it take to get CLIA waiver for a POCT device?

The timeline varies but typically ranges from 12 to 24 months from the start of waiver study planning to FDA decision. The waiver study itself (design, site selection, enrollment, testing, data analysis) usually takes 6–12 months. The FDA review of the waiver application typically takes 6–12 months. Many manufacturers submit the CLIA waiver application concurrently with or shortly after the 510(k) submission to minimize the gap between marketing clearance and waiver availability.

Can a POCT device be marketed in the US without CLIA waiver?

Yes. A POCT device can be marketed with moderate or high complexity CLIA categorization. However, this significantly limits the market because the device can only be used at sites with moderate or high complexity CLIA certificates — which excludes the majority of physician offices, pharmacies, and other non-laboratory settings. Most POCT manufacturers pursue CLIA waiver as a priority, though some devices (e.g., complex blood gas analyzers) are inherently moderate complexity and do not seek waiver.

What is the difference between a CLIA waiver study and a 510(k) clinical study?

The 510(k) clinical study compares the new device's performance to a predicate or reference method, typically in the hands of trained laboratory professionals, to demonstrate substantial equivalence. The CLIA waiver study specifically evaluates the device's performance in the hands of non-laboratory-trained operators at intended waived-test sites, to demonstrate simplicity and insignificant risk of erroneous results. Both studies involve method comparison, but the waiver study focuses on whether untrained operators can achieve acceptable performance using only the device's labeling.

How does the EU IVDR classify POCT devices differently from the IVDD?

Under the old EU In Vitro Diagnostic Directive (IVDD, 98/79/EC), most POCT devices — including many self-testing devices — were in the "Other" category and could be self-certified by the manufacturer without Notified Body involvement. Under IVDR, the risk-based classification system (Classes A through D) applies to all IVDs, and self-testing devices are automatically up-classified by one class. This means many POCT devices that were previously self-certified now require Notified Body review, representing a significant increase in regulatory burden for POCT manufacturers selling in Europe.

What is ISO 22870 and is it mandatory?

ISO 22870 (Point-of-care testing — Requirements for quality and competence) is an international standard that specifies quality management requirements for POCT performed in healthcare organizations. It is not universally mandatory by law, but it is referenced by many accreditation organizations (e.g., CAP, Joint Commission, ISO 15189 accreditation bodies) and is considered best practice for POCT quality management. In some jurisdictions and for some accreditation programs, compliance with ISO 22870 is required. Even where not explicitly required, implementing ISO 22870 is strongly recommended because it provides a structured framework for managing the unique quality challenges of decentralized testing.

What are the biggest quality risks in POCT?

The most common quality issues in POCT programs include: (1) operator errors due to inadequate training or competency, (2) failure to perform required quality control, (3) use of expired reagents, (4) failure to capture results in the patient's medical record, (5) testing performed by unauthorized or non-competent operators, (6) specimen collection errors (wrong specimen type, hemolysis, clotting), (7) device malfunction or calibration issues not detected due to infrequent QC, and (8) lack of POCT coordinator oversight in distributed testing environments. Strong connectivity (middleware/data managers), operator lockout, QC lockout, and a robust POCT coordinator program mitigate these risks.

How is POCT reimbursed in the US?

POCT is reimbursed through CPT codes, which are the same codes used for laboratory testing. There is no separate "POCT" fee schedule — the reimbursement is based on the analyte tested, not the testing methodology. However, the QW modifier is appended to CPT codes to indicate that the test was performed as a CLIA-waived test. Reimbursement rates for POCT may be the same as or lower than central laboratory testing for the same analyte, which creates a financial challenge because POCT typically has higher per-test reagent costs. The business case for POCT is often driven by improved clinical workflow, reduced length of stay, or improved outcomes rather than direct test-level profitability.

What is the future of molecular POCT?

Molecular POCT is one of the fastest-growing segments of the POCT market. The current generation of molecular POCT platforms (Cepheid GeneXpert, Abbott ID NOW, Roche cobas Liat, bioMerieux BioFire) has demonstrated that nucleic acid amplification testing can be performed at or near the point of care with turnaround times of 15–60 minutes. The next generation of molecular POCT is expected to deliver: (1) true instrument-free molecular detection (CRISPR-based, isothermal with lateral flow readout), (2) multiplexed panels with 10+ targets in a single POCT cartridge, (3) antimicrobial resistance detection at the point of care, (4) cost reduction through simplified manufacturing and higher volumes, and (5) integration of molecular POCT results with AI-powered clinical decision support. The long-term vision is molecular testing as accessible and inexpensive as today's lateral flow antigen tests, with sensitivity approaching central laboratory PCR.

Can POCT replace central laboratory testing?

POCT will not replace central laboratory testing, but it will increasingly complement it. Central laboratories offer advantages that POCT cannot match: comprehensive test menus (hundreds of analytes), superior analytical performance, lower per-test cost at volume, established quality management, and specialized testing capabilities (mass spectrometry, flow cytometry, advanced molecular). However, for time-critical analytes where rapid turnaround changes clinical management — cardiac troponin, blood gases, glucose, infectious disease identification — POCT is becoming the standard of care. The future model is a hybrid laboratory network where POCT handles the time-sensitive, high-volume, and geographically distributed testing, while central laboratories handle the complex, specialized, and high-volume batch testing.

What changed with the 2025 CLIA updates for POCT?

The January 2025 CLIA regulatory updates represent the first major overhaul of CLIA requirements in decades. Key changes include: (1) HbA1c becoming a regulated analyte for proficiency testing, with CMS setting a +/- 8% performance range and CAP using a +/- 6% accuracy threshold, (2) nursing credentials no longer automatically qualifying personnel for high-complexity testing, though new alternative pathways are available, and (3) enhanced Technical Consultant qualification requirements for new appointments. Additionally, CMS is transitioning to fully electronic CLIA communications by March 2026, ending paper certificates and fee coupons. POCT programs should review their personnel qualifications, PT enrollment, and contact information with their state CLIA agency to ensure compliance.

Do state regulations add requirements beyond federal CLIA?

Yes, and this is a common source of confusion. While CLIA sets the federal floor, many states impose additional requirements. New York and Washington operate their own laboratory programs with standards exceeding CLIA. Other states may require specific credentials for testing personnel, limit which professionals can order or perform POCT, impose additional laboratory director requirements, or require state-specific reporting of certain test results. Pharmacy-based POCT is particularly affected by state variation — the authority for pharmacists to order, perform, interpret, and act on POCT results differs state by state and is often governed by multiple state laws simultaneously. Always consult state-specific requirements before implementing a POCT program.

What is the REASSURED criteria for POCT?

The REASSURED criteria (an update to the WHO's original ASSURED framework) define the ideal characteristics for point-of-care diagnostic tests, particularly for resource-limited settings. REASSURED stands for: Real-time connectivity (results transmitted to surveillance systems), Ease of specimen collection (non-invasive specimens preferred), Affordable, Sensitive, Specific, User-friendly, Rapid and robust, Equipment-free (minimal instrumentation), and Deliverable to end-users. The framework is widely used to evaluate POCT suitability for global health applications and is increasingly referenced in the development of next-generation POCT platforms for both low-resource and high-resource settings.

How does POCT support antimicrobial stewardship?

POCT plays an increasingly important role in antimicrobial stewardship by enabling more targeted antibiotic prescribing. Key applications include: (1) CRP POCT in primary care, which helps distinguish bacterial from viral respiratory infections and has been shown in multiple trials to reduce unnecessary antibiotic prescribing by 20–40%, (2) rapid strep A tests that enable targeted treatment of bacterial pharyngitis, (3) rapid influenza and COVID-19 tests that confirm viral etiology and avoid empiric antibiotics, and (4) emerging rapid antimicrobial susceptibility testing (AST) at the point of care. Procalcitonin POCT is also emerging as a tool for guiding antibiotic de-escalation in emergency departments and ICUs. Given that the WHO has identified antimicrobial resistance as a top-ten global public health threat, the role of POCT in antimicrobial stewardship is expected to grow significantly.